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Abstract
Background: Cigarette smoking is a leading preventable risk factor for the devel-
opment and progression of cardiovascular diseases (CVDs). Epidemiologic studies in
smokers confirm the association between the alteration in lipid profile levels and
CVDs risk. Fibrinogen, an acute phase reactant with active involvement in endothelial
function, thrombosis and inflammation. It is signified as a systemic marker of carotid
atherosclerosis. The purpose of this study was to assess the level of fibrinogen and
lipid parameters in Sudanese tobacco smokers.
Methods: This case-control study included 55 adult male of a current smoking status;
their ages ranged between 18 and 54 years, and 100 non-smokers considered as
controls. We evaluated the effect of cigarette smoking on plasma fibrinogen and
serum lipid profile. The American Heart Association guidelines and reference ranges
were used to identify the smokers with increased risk of coronary heart disease.
Results: Our study revealed an increase in the levels of fibrinogen, total cholesterol,
and low-density lipoprotein cholesterol (LDL-C) among smokers than controls,
whereas the mean level of and triglycerides did not differ. The levels of high-
density lipoprotein cholesterol HDL-C demonstrated decrement. Further, smokers
were classified according to the atherogenic risk index LDL-C/HDL-C ratio, the
studied parameters fibrinogen, total cholesterol, and triglycerides were significantly
increased in those who have ratio 4.5 and more (p = 0.001, p = 0.018, p = 0.007,
respectively). Smokers with atherogenic index ≥ 4.5 were more likely to have ≥ 300
mg/dl fibrinogen level (odds ratio (OR) 3.96, 95% confidence interval (95%CI) 1.14–
13.73, p = 0.026). Moreover, the level of the fibrinogen can be predicted by linear
regression equation: Fibrinogen level = 19.49 + 79.08 (the ratio of LDL-C ⁄HDL-C), r =
0.37, p = 0.008, 95%CI 21.20–136.95. Conclusion: Increased fibrinogen, LDL-C, and LDL-
C/HDL-C ratio may potentiate the development of cardiovascular disease in smokers.
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1. Introduction
The tobacco epidemic is one of the biggest public health threats the world affronted,
killing around 6 million people a year. More than 5 millions of those deaths are the
result of direct tobacco use. Nearly 80% of the more than 1 billion smokers world-
wide live in low- and middle-income countries with increased risk to cardiovascular
diseases (CVDs) [1, 2]. Smoking is estimated to cause nearly 10% of CVDs. The risk
of CVDs mortality for persons who smoke cigarettes is about double that of lifetime
non-smokers [3]. Disease risk due to smoking is not limited to smokers only, passive
smoking, exposure to environmental tobacco smoke, is associated with adverse health
effects, and it increases the risk of several diseases [4]. The smokers and passive
smokers have a different lifestyle than non-smokers, as these people consume more
calories, fat, and alcohol, and less fibre, fruit, vegetables, vitamin supplements, and
useful oilseeds, which increase the incidence of atherosclerosis and coronary artery
diseases in smokers [5].
Several studies confirm that smoking increases the level of inflammatory markers
in blood as white blood cell count, fibrinogen, and C-reactive protein [6, 7]. Smokers
have high-level total cholesterol (TC) and LDL cholesterol (LDL-C) levels and lower
HDL cholesterol (HDL-C) levels exacerbating the risk of myocardial infarction, sudden
cardiac death, stroke, peripheral vascular disease [8]. Most of the proposed proathero-
genic actions of smoking, such as interference with blood coagulation, induction of
endothelial dysfunction, and promotion of lipid per oxidation, reverse themselves
shortly after cessation of smoking [9].
Fibrinogen is a plasma glycoprotein produced by hepatocytes in response to
interlukin-1, interleukin-6, and tumour necrosis-α during acute severe infections [10,
11]. There is growing evidence fromprospective studies that a higher plasma fibrinogen
concentration is associated with increased risk, incidence, and severity of coronary
heart disease [12–14]. Various studies suggested association between smoking status
and elevated fibrinogen levels [15–18]. The purpose of this study was to assess the
level of fibrinogen and lipid profile parameters in Sudanese tobacco smokers.
2. Materials and Methods
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2.1. Study design and study subjects
The present study has been approved by the Faculty of Medicine, University of Gezira
Ethics Committee. Furthermore, all smokers signed the formal consent before data and
sample collection. This case-control recruited 55 male cigarettes smokers and 100 age–
sex-matched non-smokers. All of them were from the Gezira state – Wad-Medani city,
Sudan. A questionnaire was designed to collect personal information, clinical data, and
smoking history from each participant. The study participants were clinically evalu-
ated for their health, none of the participant reported to have diseases/disorders or
medications that affect fibrinogen level or lipid parameters.
Blood samples were collected from participants in sodium citrate to measure plasma
fibrinogen, and plain container for serum lipid profile estimation. All the blood samples
were centrifuged at 3000rpm for 5 min at the room temperature and plasma lipid
profile with fibrinogen were measured immediately. Automated analyzer accent-200
was used to estimate plasma fibrinogen by immuno-turbidimetric assay; and lipid
profile by enzymatic spectrophotometric method.
2.2. Statistical analysis
Statistical analysis was carried out using Statistical Package for Sciences (SPSS, version
20). Data were expressed as mean ± standard error of mean (SEM) and compared
firstly with controls and secondly with the provided reference values of the reagents
and the data published in the literature. The smokers were stratified according to the
atherogenic index (LDL-C/HDL-C) into two groups, group I (less than 4.5) and group
II (4.5 and more), means of continuous variables were compared between the two
groups using t-test. Then, the logistic regression analysis was performed to measure
the risk estimate by odds ratio, 95% confidence intervals (95%CI), and p-value of
having high concentrations of fibrinogen level in the two atherogenic groups. Besides,
the linear regression test was applied to predict the level of fibrinogen in smokers
using the atherogenic index.
3. Results
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3.1. The general characteristics of the study group and
the comparison of the measured parameters
Smokers’ ages ranged between 18 and 54 years with themean age of 27.60± 0.95. The
mean smoking duration was 6.6 ± 0.66 years and the average number of cigarettes
per smoker per day was 9.8 ± 1.56.
Table 1 shows the measured lipid profile parameters and fibrinogen level in the
two groups, levels of cholesterol, LDL-C, and fibrinogen were significantly increased
in smokers than non-smokers (p < 0.0001). The HDL-C was markedly decreased in the
smokers group, while the triglycerides level did not differ.
T 1: Lipid parameters and fibrinogen level in smokers and non-smokers groups.
Parameters Smokers (n = 55) Non-smokers (n = 100) p-value
Cholesterol (mg/dl) 185.11 ± 4.72 133.31 ± 1.81 < 0.0001
HDL-C (mg/dl) 29.91 ± 0.85 55.14 ± 2.03 < 0.0001
LDL-C (mg/dl) 145.76 ± 3.10 86.28 ± 1.37 < 0.0001
Triglycerides (mg/dl) 126.07 ± 3.81 120.90 ± 5.13 0.4904
Fibrinogen (mg/dl) 423.44 ± 33.91 284.98 ± 4.15 < 0.0001
3.2. The risk of developing cardiovascular disease among
smokers based on the reference range of lipid parameters
and fibrinogen
The mean levels of lipid profile and fibrinogen in smokers were compared to the
reference ranges of the American Heart Association [19] displaying the percentage of
smoker who are at risk of cardiovascular diseases. According to the published guide-
lines, Table 2 shows that 12.73% of the smokers were at high risk of developing CVDs.
The HDL-C showed a marked decrease, 92.73% of the whole group with increased risk.
The LDL-C level was increased as compared with the reference range, 32.73% of the
smokers were highly susceptible to CVDs risk. For the atherogenic index LDL-C⁄HDL-C,
the mean was 5.05 ± 0.17, indicating that the studied smokers were at high risk. Of
the 55 smokers, only 16.36% had borderline high triglycerides. The fibrinogen level
423.44 mg/dl was high when compared with the reference range (365 mg/dl) of the
American Heart association.
Normal plasma fibrinogen levels range were defined as 200–400 mg/dl, and hyper-
fibrinogenemia was defined as plasma fibrinogen concentrations greater than 400
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T 2: Mean levels of the lipid parameters and fibrinogen, and risk participants according to the reference
ranges.





Cholesterol (mg/dl) 185.11 ± 4.72 3.64% 12.73%
HDL-C (mg/dl) 29.91 ± 0.85 7.27% 92.73%
LDL-C (mg/dl) 145.76 ± 3.10 45.45% 32.73%
LDL-C⁄HDL-C 5.05 ± 0.17 18.18% 72.73%
Triglycerides (mg/dl) 126.07 ± 3.81 16.36% –
Fibrinogen level
Fibrinogen (mg/dl) 423.44 ± 33.91 27.27%|| 36.36%†
Notes: The American Heart Association guidelines: the total cholesterol optimal range
< 200mg/dl, range from 200–239mg/dl, demonstrates borderline of risk,≥ 240mg/dl
indicates high risk to CVDs; optimal LDL-C in the range < 100 mg/dl, while 100–129
mg/dl considered as near optimal, 130–150 mg/dl defines the borderline risk and ≥
160mg/dl the high CVDs risk; HDL-C < 60 mg/dl specifies the group of adult men at
the borderline risk, while the high CVDs risk men are classified at < 40 mg/dl; the
hypertriglycerideamia denotes borderline risk at 150–190 mg/dl, and ≥ 200 mg/dl
represents the high-risk group; the LDL-C⁄HDL-C ≥ 4.5 indicates high atherogenic risk.
mg/dl [20]. || specifies smokers with fibrinogen level ≤ 400mg/dl, † indicates smokers
with fibrinogen level > 400mg/dl.
3.3. Comparing levels of cholesterol, triglycerides, and fibrinogen
between atherogenic groups
The study group was stratified according to the LDL-C ⁄HDL-C ratio into low-risk group
of less than 4.5 (group I) and high-risk group that had 4.5 andmore (group II). The level
of cholesterol was higher in group II compared to group I, the difference between the
two group was statistically significant (p = 0.018). The mean serum triglycerides was
significantly higher in group II than in group1(p = 0.007). Group II, the high atherogenic
risk group, showed conspicuous increase in fibrinogen level compared to group I (p =
0.001). All these data are demonstrated in Table 3 and Figure 1.
T 3: The mean levels of cholesterol, triglycerides, and fibrinogen in smokers atherogenic groups.
Variables Atherogenic < 4.5
Group I (n = 15)
Atherogenic ≥ 4.5
Group II (n = 40)
p-value
Cholesterol 168.73 ± 7.06 191.25 ± 5.67 0.018
Triglycerides 111.47 ± 5.32 131.55 ± 4.58 0.007
Fibrinogen 293.00 ± 27.21 472.35 ± 43.18 0.001
Note: LDL-C and HDL-C levels were not represented in the variables because they
were expressed as LDL-C/HDL-C ratio (atherogenic index).
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3.4. Risk estimate for cardiovascualar diseases using LDL-C⁄HDL-C
ratio and fibrinogen level
The risk estimate of having high fibrinogen as a risk factor for cardiovascular events
was assessed in smokers using logistic regression analysis (Table 4). No significant
associationwas observed between the level of total cholesterol, LDL-C, or triglycerides.
Considerably, the smokers with atherogenic index ≥ 4.5 are 3.96%more likely to have
high fibrinogen ≥ 300 mg/dl and hence more vulnerable to cardiovascular diseases (p
= 0.026).
T 4: Frequency of smokers and risk estimate of having high fibrinogen according to the normal and
high ranges of total cholesterol, LDL-C, triglycerides levels, and LDL-C⁄HDL-C ratio.
LDL-C⁄HDL-C ratio Fibrinogen level p-value (OR, 95%CI)
≥ 300 mg/dl < 300 mg/dl
Cholesterol ≥ 200 26 14 0.73 (0.81, 0.24–2.74)
Cholesterol < 200 9 6
LDL-C ≥ 130 31 15 0.20 (2.58, 0.61–11.04)
LDL-C < 130 4 5
TG ≥ 150 7 2 0.34 (2.25, 0.42–12.06)
TG < 150 28 18
Atherogenic ≥ 4.5 29 11 0.026 (3.96, 1.14–13.73)
Atherogenic < 4.5 6 9
Note: HDL-C was removed from the logistic regression model because all smokers were
having HDL-C < 60mg/dl.
Figure 1: The correlate of fibrinogen level to the LDL-C/HDL-C ratio.
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4. Discussion
Smoking has been recognized as an important risk factor for the CVDs, attributed to
the alterations of the plasma fibrinogen and lipoprotein pattern [21, 22]. Our study was
conducted to evaluate the level of fibrinogen and lipid profile in Sudanese smokers.
According to the reference range of the fibrinogen level, the study showed increased
mean level of fibrinogen among Sudanese smokers. This result was supported by
several global studies, which confirmed an increased level of fibrinogen among smok-
ers [22–24]. In Sudan, a comparative study was done that revealed the increase of
fibrinogen level among healthy smokers, whereas the level was decreased among
non-smokers and ceased smokers, plasma fibrinogen may remain elevated for several
years after cessation [25, 26]. In that scenario, it was proved that a primary role for
increased synthesis in producing the hyperfibrinogenaemia associated with smoking:
an influential study for smokers showed that cessation from smoking for a period of
only two weeks induces a significant decrease in the rate of fibrinogen synthesis by
the liver, with a concomitant reduction in the plasma fibrinogen concentration [27].
The association between fibrinogen and carotid atherosclerosis was investigated;
high incidence of carotid atherosclerosis was reported among smokers, whilst this
trend was not manifested for non-smokers or former smokers [17]. In this study,
92.73% of the smokers showed low HDL-C level < 40mg/dl, and 72.73% of the
smokers have ≥ 4.5 LDL-C ⁄HDL-C ratio. Highest fibrinogen levels were observed in
smokers with high atherogenic risk. Clinical studies have documented that fibrinogen
is not only a blood coagulation factor but also an inflammatory marker, influencing
leukocyte recruitment, and particularly modulating the adhesive behaviour of the
neutrophils [28]. A number of studies reported that a high plasma fibrinogen level is an
independent and major risk marker of cardiovascular diseases [29–31]. In a population
sample of adults without clinically obvious atherosclerotic disease, elevated fibrinogen
levels ascertained to be associated to carotid intima-media thickness, representing a
systemic marker of carotid atherosclerosis [32]. In the same consensus, cigarette
smoking linked with elevated serum levels of cholesterol, LDL-C, triglycerides, and
lower plasma concentrations of HDL-C than non-smoker [33, 34].
Our study does not indicate extreme deviation from normal reference ranges. Similar
results were obtained from controlled clinical trial in Polish smokers; higher lipid values
with elevated lipid peroxidation products were found when compared with the non-
smokers’ group, annotating the cigarette-smoking risk in the onset of atherosclerosis
and coronary heart disease [35]. Nicotine and carbon monoxide seem to play a major
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role in the effect of smoking on vessels. In addition to its acute haemodynamic effects,
tobacco not only has an atherogenic effect (endothelial toxicity and changes in lipid
profile), but it also facilitates thrombosis (by alteration of platelet functions and eleva-
tion of fibrinogen level, haematocrit level and blood viscosity) and vascular contraction
(through modification of prostaglandin metabolism and action on catecholamines or
decrease of nitric oxide production) [36].
Smoking in adolescence and young adulthood might increase the risk of cardiovas-
cular events [34]. In this study, it is worth pointing out that 60% of the study smokers
with age less than 35 years, younger smokers give prediction to longer smoking dura-
tion and hence aggravating the risk of dyslipidaemia. Confirmation to this suggestion,
the smokerswith high atherogenic index aremore likely to have higher fibrinogen level
increasing their vulnerability to develop cardiovascular events. Our data showed that
this linear correlation between fibrinogen and atherogenic index was substantiated by
the following equation: Fibrinogen level = 19.49 + 79.08 (the ratio of LDL-C⁄HDL-C), r
= 0.37, p = 0.008. Hence, smokers with LDL-C ⁄HDL-C ratio = 4.5 might have fibrinogen
level 375.35 mg/dl.
5. Conclusion
Significant elevation of fibrinogen, LDL-C Levels, and LDL-C ⁄HDL-C ratio concomi-
tant with significant decrease in serum HDL-C concentration were remarked among
Sudanese smokers. Smokers with high atherogenic index are more liklely to have
increased level of fibrinogen. It was suggested that the increase of fibrinogen level in
addition to alterations of lipid profile increase the risk of cardiovascular disease among
Sudanese smokers.
6. Limitations of the Study
Overall, the study included a small number of smokers, and little attention was paid to
post-study follow-up.
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